ReviewAustralian prescriber2025
Drug safety in pregnancy.
Review in Australian prescriber, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Sterol biosynthesis, brain development, and disease.The Journal of clinical investigation · 2026Review
- Sodium valproate: balancing benefits and risks especially in people of childbearing potential.Australian prescriber · 2026Review
- Letter to Editor "Comments on self-medication with conventional and herbal medicines in pregnancy: prevalence and factors in Northwest Ethiopia".Annals of medicine and surgery (2012) · 2026Article
- Use of nervous system medications with fetal risk before and during pregnancy in an Argentine social security systemRevista colombiana de obstetricia y ginecologia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drugs can affect the fetus in various ways, with the timing of exposure during pregnancy a key factor in determining both if and how a drug will impact a developing fetus. The exclusion of women of childbearing age from clinical trials, and the challenges in conducting large epidemiological studies, have resulted in a paucity of data on the fetal and maternal safety of drugs in pregnancy. In some patients, the benefits of drug treatment may outweigh the potential risks to the fetus. It is important for prescribers to assess and communicate the benefits and risks in the context of the individual patient. The Australian categorisation system for prescribing drugs in pregnancy was implemented to guide prescribers; however, it has shortcomings and lessons can be learned from the systems of other countries. Obstetric drug information services and other evidence-based resources are available to provide guidance to healthcare professionals and consumers on the use of drugs in pregnancy and breastfeeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.